The safety of pharmacotherapy of rheumatic diseases in gestation and lactation
Journal Title: Reumatologia - Year 2006, Vol 44, Issue 6
Abstract
Rheumatic diseases frequently occur in young people, including women in the reproductive age. The problem of pregnancy is not a rare issue in this group. The decision about maintenance treatment or treatment of a flare of the disease occurring during pregnancy is always burdened with a high risk of maternal and foetal complications. The most commonly used nonsteroidal anti inflammatory drugs should be used in the lowest therapeutically sufficient dose and they should be stopped 8 weeks before the delivery. Among the glicocorticosteroids, prednisone and prednisolone have the safest profile as they are 90% metabolized in the placenta. Long-term, multicentre, retrospective studies have shown the relative safety of hydroxychloroquine, sulphasalazine and azathioprine, provided that they are used in the recommended doses under strict rheumatological and obstetrical supervision. Methotrexate, cyclophosphamide, mycophenolate mofetil and leflunomide are contraindicated in pregnancy. The reports on the safety of etanercept and infliximab during pregnancy are optimistic, however scanty. The use of cyclosporine should be limited due to increased risk of maternal and foetal complications. Low doses of nonsteroidal anti inflammatory drugs and prednisone do not exclude breastfeeding. -term, multicentre, retrospective studies have shown the relative safety of hydroxychloroquine, sulphasalazine and azathioprine, provided that they are used in the recommended doses under strict rheumatological and obstetrical supervision. Methotrexate, cyclophosphamide, mycophenolate mofetil and leflunomide are contraindicated in pregnancy. The reports on the safety of etanercept and infliximab during pregnancy are optimistic, however scanty. The use of cyclosporine should be limited due to increased risk of maternal and foetal complications. Low doses of nonsteroidal anti inflammatory drugs and prednisone do not exclude breastfeeding.
Authors and Affiliations
Lidia Ostanek, Danuta Bobrowska-Snarska, Marek Brzosko
Keywords
Related Articles
- EP ID EP118419
- DOI -
- Views 91
- Downloads 0
VII Polsko-Słowacka Konferencja Internistyczna w Katowicach (tematyka reumatologiczna). Katowice, 24–25 lutego 2006 r.
Zapalenie skórno-mięśniowe i wielomięśniowe – możliwości leczenia
Zapalenia skórno-mięśniowe (dermatomyositis, DM) i wielomięśniowe (polymyositis, PM) są rzadkimi, idiopatycznymi zapalnymi miopatiami. W przypadkach o łagodnym przebiegu DM i PM mogą przejawiać się tylko nieznacznym os...
Combination treatment in rheumatology - helpful or harmul?
Combination treatments may interact with various mechanisms of inflammatory process thus increasing efficacy and facilitating improvement in patients with rheumatic conditions. On the other hand, it may increase risk of...
Metody oceny aktywności twardziny układowej
Rozpoznanie twardziny układowej (TU) nie zawsze jest łatwe, szczególnie we wczesnym okresie choroby. Ma to związek z dużą zmiennością rozległości zmian skórnych, różnym stopniem zajęcia narządów wewnętrznych, bardzo zmie...
Test CRP wysokiej czułości w diagnostyce i monitorowaniu chorób reumatycznych
Białko C-reaktywne (C-reactive protein, CRP) należy do rodziny białek Pentaxin produkowanych w wątrobie. Zaliczono je do białek ostrej fazy, gdyż jego poziom w sposób niezwykle czuły odzwierciedla odpowiedź organizmu na...